Drug · DIN 02361701
VIMOVO
MODIFIED-RELEASE TABLET
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since February 28, 2022; first marketed February 4, 2011.
- Drug Identification Number (DIN)
- 02361701
- Company (DIN owner)
- Xediton Pharmaceuticals Inc.Oakville, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet (Immediate- And Delayed-Release)
- Route
- Oral
- Therapeutic class (ATC)
- Naproxen and esomeprazole M01AE52
- Class
- Human
- Record last updated
- August 17, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| NAPROXEN | 375 MG | |
| ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM TRIHYDRATE) | 20 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 28, 2022: NOC 27675New Drug Submission (NDS) · Administrative: Change in Product Ownership
- November 14, 2016: NOC 18749Supplement to a New Drug Submission (SNDS) · This purpose of tis supplemental new drug submission is to update tyhe labelling of vimovo with safety information with respect to interaction with antiretroviral products ;in response to health canada's advisement letter for all proton-pump inhibitors
- January 13, 2011: NOC 11998New Drug Submission (NDS)
Other DINs named VIMOVO
- DIN 02361728 · Marketed